Ganirelix
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ganirelix: From Controlled Ovarian Stimulation to Hypertrichosis
One-Sentence Summary
Ganirelix is a GnRH (gonadotropin-releasing hormone) receptor antagonist historically used in assisted reproduction to prevent premature LH surges during controlled ovarian stimulation. The TxGNN model predicts it may be effective for Hypertrichosis (disease), but currently 0 clinical trials and 0 publications support this direction — the signal comes from the AI model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Controlled ovarian stimulation (ART/IVF) — prevention of premature LH surge (no TFDA license data on file; drug not marketed in Taiwan) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Ganirelix is a GnRH receptor antagonist that suppresses pituitary gonadotropin (LH/FSH) release, which is used clinically to block premature ovulation during controlled ovarian stimulation cycles.
Hypertrichosis is an etiologically heterogeneous condition (congenital, drug-induced, or androgen-excess driven). Since GnRH antagonism suppresses downstream gonadal steroidogenesis, there is a theoretical, indirect rationale that suppressing androgen production could dampen androgen-driven hair growth in some hypertrichosis subtypes.
However, this mechanistic link is speculative rather than established: hypertrichosis is a heterogeneous phenotype, and no clinical or preclinical study has tested Ganirelix in this context. The prediction should be treated as a hypothesis-generating signal only, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Ganirelix has no marketing authorization records in this dataset (0 licenses on file; market status: not marketed). No product/dosage-form/indication table is available.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score, there is zero supporting clinical trial or literature evidence, and the proposed mechanistic link between GnRH antagonism and hypertrichosis is indirect and speculative. This does not meet the bar to advance past initial screening (S0).
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for Ganirelix
- TFDA/SmPC label warnings and contraindications (currently blocking — flagged as DG001)
- Preclinical or case-level evidence linking GnRH antagonism to androgen-driven hair growth suppression
- Clarification of which hypertrichosis subtype (androgen-dependent vs. congenital/structural) would plausibly respond, since most subtypes have no hormonal basis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.